Literature DB >> 2684296

Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia.

P C Cogswell1, R Morgan, M Dunn, A Neubauer, P Nelson, N K Poland-Johnston, A A Sandberg, E Liu.   

Abstract

Seventy cases of chronic myelogenous leukemia (CML) were analyzed for the presence of ras mutations using polymerase chain reaction (PCR), oligonucleotide hybridization, and direct PCR sequencing. All cases had preceding cytogenetic and bcr rearrangement studies. Aberrant ras genes were detected in none of 39 patients with Philadelphia (Ph) chromosome or bcr/abl rearrangement positive chronic-phase CML and in only 1 of 18 patients in blast crisis, suggesting that ras mutations have little or no role in initiation or progression of common CML. Seven of 13, or 54% of patients with bcr/abl rearrangement negative chronic phase CML (atypical CML) harbored mutations in ras, however. This high incidence of ras mutations, together with the absence of bcr/abl rearrangement, provides evidence that atypical CML is an entity that is molecularly distinct from common CML. Moreover, the clinical characteristics and the high frequency of ras mutations suggest that atypical CML may constitute a subset of the myelodysplastic syndrome and may be best classified as a variant of chronic myelomonocytic leukemia (CMML).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2684296

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer.

Authors:  L C Chen; A Neubauer; W Kurisu; F M Waldman; B M Ljung; W Goodson; E S Goldman; D Moore; M Balazs; E Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

Review 2.  Protein kinases in human breast cancer.

Authors:  W G Cance; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

3.  Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Authors:  Emma M C Driessen; Eddy H J van Roon; Jill A P Spijkers-Hagelstein; Pauline Schneider; Paola de Lorenzo; Maria Grazia Valsecchi; Rob Pieters; Ronald W Stam
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

Review 4.  What's different about atypical CML and chronic neutrophilic leukemia?

Authors:  Kim-Hien T Dao; Jeffrey W Tyner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

5.  A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples.

Authors:  Prashanth Setty; Jennifer Hammes; Thomas Rothämel; Valentina Vladimirova; Christof M Kramm; Torsten Pietsch; Andreas Waha
Journal:  J Mol Diagn       Date:  2010-09-16       Impact factor: 5.341

Review 6.  Farnesyltransferase inhibitors in myelodysplastic syndrome.

Authors:  E J Feldman
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 4.213

7.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.

Authors:  C L Sawyers; J McLaughlin; O N Witte
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.